MAIA Biotechnology, Inc. Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations
MAIA Biotechnology, Inc. (MAIA) reported Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations of $18.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectDisposalGroupIncludingDiscontinuedOperations · last filed 2026-08-10
- MAIA Biotechnology, Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect disposal group including discontinued operations for the quarter ending 2026-03-31 was $25.76M, a 1940.82% increase year-over-year.
- MAIA Biotechnology, Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect disposal group including discontinued operations for the quarter ending 2025-03-31 was $1.26M.
- MAIA Biotechnology, Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect disposal group including discontinued operations for fiscal 2025 was -$943.27K, a 138.49% decline from fiscal 2024.
- MAIA Biotechnology, Inc. cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect disposal group including discontinued operations for fiscal 2024 was $2.45M.
| Period end | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations 3 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations 6 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations 9 month | Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Disposal Group Including Discontinued Operations 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.94M 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $25.76M 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | -$943.27K 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.29M 10-Q · filed 2025-11-07 | |||
| 2025-06-30 | $543.22K 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $2.45M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $1.54M 10-Q · filed 2025-11-07 | |||
| 2024-06-30 | $4.43M 10-Q · filed 2025-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |